Evidence map›Paper›PMID 38052324›Full record

ArticleUrology2024

Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.

Kristin Weiss, Obafunbi Abimbola, Kelsey Miller, William Y Kim, Tracy L Rose, Marc A Bjurlin, Kathryn H Gessner

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kristin WeissUniversity of North Carolina School of Medicine, Chapel Hill, NC.
Obafunbi AbimbolaDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Kelsey MillerDepartment of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
William Y KimLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Tracy L RoseLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Marc A BjurlinDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Kathryn H GessnerDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: Kathryn_gessner@unchealth.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

UNC Integrated Translational Oncology Program (UNC-iTOP)T32CA244125 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAM Y. KIM, Jen Jen Yeh · 2019 to 2026
$3.9M
NCI NIH HHS T32 CA244125
6 · The paper itself

Abstract

In bladder urothelial carcinoma, ERBB2 mutations have been associated with favorable response to platinum-based neoadjuvant chemotherapy. However, this association has not been reported in upper tract urothelial carcinoma (UTUC). We describe an excellent response to cisplatin-based chemotherapy in metastatic UTUC with an ERBB2 mutation. Our patient is a 54-year-old female with metastatic UTUC who received systemic cisplatin and gemcitabine. Postchemotherapy imaging demonstrated decreased size of pyelocaliceal mass and decreased retroperitoneal adenopathy compared to initial imaging. Surgical pathology from consolidative resection showed 3 mm residual renal tumor and no viable lymph node disease. Genomic testing demonstrated an ERBB2 gain of function mutation.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsCisplatinErb-b2 Receptor Tyrosine KinasesFemaleGenes, erbB-2HumansMiddle AgedMutationNeoplasm, ResidualPathologic Complete ResponsePlatinumCisplatinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPlatinum

Identifiers

PMID38052324
PMCPMC11364485
OpenAlexW4389285474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.